Solutions
About Us
Insights
Careers

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. O’Donnell HK, Simmons KM, Gitelman SE, Dex T, Hill R, Wieloch M, Zaccai J, D’Souza J, Ginchereau Sowell F, Turnbull J, Hood KK. Diabetes Obes Metab. 2025

Influence of Treatment Effect Modifiers in Fabry Disease: A Systematic Literature Review. Azimpour K, Tordoff-Gibson C, Dorling P, Koulinska I, Kunduri S, Laliman-Khara V, Forsythe A. Adv Ther. 2025

Developing a prototype for federated analysis to enhance privacy and enable trustworthy access to COVID-19 research data. Eradat Oskoui S, Retford M, Forde E, Barnes R, J Hunter K, Wozencraft A, Thompson S, Orton C, Ford D, Heys S, Kennedy J, McNerney C, Peng J, Ghanbariadolat H, Rees S, H Mulholland R, Sheikh A, Burgner D, Brockway M, B Azad M, Rodriguez N, Zoega H, J Stock S, Calvert C, E Miller J, Fiorentino N, Racine A, Haggstrom J, Postlethwaite N. Int J Med Inform. 2025

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. Perdrizet J, Ta A, Huang L, Wannaadisai W, Ilic A, Hayford K, Sabra A. Infect Dis Ther. 2025

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme. Çakar E, Ta A, Peters M, Vinand E, Waterval-Overbeek A, Ilic A, Perdrizet J. Infect Dis Ther. 2025

Long-term risk of HCC in a DAA-treated national hepatitis C cohort, and a proposed risk score. Lybeck C, Bruce D, Szulkin R, Montgomery S, Aleman S, Duberg AS. Infect Dis (Lond). 2025

Conus medullaris termination: Assessing safety of spinal anesthesia in the L2-L3 interspace. Paul JE, Udovic LA, Oman K, Kim T, Bernstein L, Matteliano L, Singh N, Caldwell A, Vanniyasingam T, Thabane L. Acta Anaesthesiol Scand. 2025

Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis. Krieger J, Cox O, Flacke JP, Beilschmidt L, Mueller S, Maywald U, Koss MJ. Graefes Arch Clin Exp Ophthalmol. 2025

Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis. Avila RL, Croteau NS, Tang F, Simeone JC, Jomaa K, Bian B, Gianinazzi M. Ther Adv Neurol Disord. 2025

Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials. Azimpour K, Dorling P, Koulinska I, Kunduri S, Lan Z, Poritz J, Tremblay G, Raad-Faherty A. Adv Ther. 2025